Key result
Lipid lowering, estrogen therapy, and hypertension control trials have advanced the understanding of the pathophysiology and prevention of coronary atherosclerosis.
Key points are not available for this paper at this time.
Design
Review
May guide risk factor modification in practice; leaves open optimal strategies pending further trials.
Over the past year, significant new advances have been made in preventive cardiology. New trials of lipid lowering, estrogen therapy, and hypertension control have added to our understanding of the pathophysiology and prevention of coronary atherosclerosis. This review highlights these new trials and provides insight into their applications in the practice of cardiology.
No takes yet. Share an insight, caveat, or question.
Jo Anne Micale Foody (1999) studied this question. Lipid lowering, estrogen therapy, and hypertension control trials have advanced the understanding of the pathophysiology and prevention of coronary atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: